ENA713

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Alzheimer's DementiaAlzheimer's Disease

Phase 3

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

CompletedNCT01614886

Novartis PharmaceuticalsAlzheimer's Disease

Start: 2012-07-31End: 2014-05-31Updated: 2016-08-01

Phase 4

Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia

CompletedNCT01585272

Novartis PharmaceuticalsAlzheimer's Dementia

Start: 2012-08-31End: 2015-06-30Updated: 2018-04-18

16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients

CompletedNCT01948791

Novartis PharmaceuticalsAlzheimer's Disease

Start: 2014-08-31End: 2015-09-30Updated: 2017-02-13